Elsevier

Analytical Biochemistry

Volume 401, Issue 1, 1 June 2010, Pages 134-143
Analytical Biochemistry

Statistical significance analysis of nuclear magnetic resonance-based metabonomics data

https://doi.org/10.1016/j.ab.2010.02.005Get rights and content

Abstract

Use of nuclear magnetic resonance (NMR)-based metabonomics to search for human disease biomarkers is becoming increasingly common. For many researchers, the ultimate goal is translation from biomarker discovery to clinical application. Studies typically involve investigators from diverse educational and training backgrounds, including physicians, academic researchers, and clinical staff. In evaluating potential biomarkers, clinicians routinely use statistical significance testing language, whereas academicians typically use multivariate statistical analysis techniques that do not perform statistical significance evaluation. In this article, we outline an approach to integrate statistical significance testing with conventional principal components analysis data representation. A decision tree algorithm is introduced to select and apply appropriate statistical tests to loadings plot data, which are then heat map color-coded according to P score, enabling direct visual assessment of statistical significance. A multiple comparisons correction must be applied to determine P scores from which reliable inferences can be made. Knowledge of means and standard deviations of statistically significant buckets enabled computation of effect sizes and study sizes for a given statistical power. Methods were demonstrated using data from a previous study. Integrated metabonomics data assessment methodology should facilitate translation of NMR-based metabonomics discovery of human disease biomarkers to clinical use.

Section snippets

Data collection

The urine and fecal data used for the data analysis were collected in a previously published study by Romick-Rosendale and coworkers [27]. PCA of urine, as well as fecal extracts, of control and antibiotic-treated mice showed minimal or no overlap in PCA scores plots, providing a near ideal test data set for demonstration of the statistical significance analysis algorithm outlined in the article.

Statistical significance analysis

Bucket tables were generated using AMIX (Bruker Biospin, Billerica, MA, USA). NMR spectra were

Decision tree algorithm

The first step in developing a rigorous statistical significance analysis approach for NMR-based metabonomics data is to determine the appropriate tests to obtain P scores for buckets corresponding to PCA loadings plot points. Due to the nature of NMR-based metabonomics data, which can involve small numbers of subjects in pilot studies, different numbers of subjects in control and treated/disease groups, and data for which the variance is generally different for each group—all of which impact

Conclusion

The ultimate goal of NMR-based metabonomics research is discovery of human disease biomarkers and translation to clinical use. Although the technology shows substantial promise, hardly any human disease biomarkers discovered using NMR-based metabonomics have been translated to clinical use at this time. One substantial obstacle is that multivariate statistical PCA-driven methods widely used by investigators conducting basic metabonomics research do not routinely subject data to rigorous

Acknowledgments

The authors acknowledge financial support from Bruker Biospin that enabled this study. M.A.K. acknowledges support from the Ohio Eminent Scholar program, Ohio Board of Regents, and Miami University for support that enabled establishing and outfitting the Eminent Scholar laboratory with the high field NMR instrumentation used in this study.

References (36)

  • N.J. Serkova et al.

    Metabolomics of cancer

    Methods Mol. Biol.

    (2009)
  • J.L. Spratlin et al.

    Clinical applications of metabolomics in oncology: a review

    Clin. Cancer Res.

    (2009)
  • N.J. Serkova et al.

    NMR-based metabolomics: translational application and treatment of cancer

    Curr. Opin. Mol. Ther.

    (2007)
  • W.M. Claudino et al.

    Metabolomics: available results, current research projects in breast cancer, and future applications

    J. Clin. Oncol.

    (2007)
  • M.G. Swanson et al.

    Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy

    Magn. Reson. Med.

    (2006)
  • K.W. Jordan et al.

    NMR-based metabolomics approach to target biomarkers for human prostate cancer

    Expert. Rev. Proteomics

    (2007)
  • J. Scheidler et al.

    Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging—clinicopathologic study

    Radiology

    (1999)
  • A. Sreekumar et al.

    Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

    Nature

    (2009)
  • Cited by (0)

    View full text